SCHEMBL7989152

SCHEMBL7989152

O=C(Nc1ccccc1NC(=O)c1ccccn1)c1ccccn1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.77
HDAC6 Q9UBN7 2/20 0.77
HDAC3 O15379 1/20 0.77
HDAC4 P56524 1/20 0.77
HDAC7 Q8WUI4 1/20 0.77
HDAC2 Q92769 1/20 0.77
HDAC10 Q969S8 1/20 0.77
HDAC11 Q96DB2 1/20 0.77
HDAC8 Q9BY41 1/20 0.77
HDAC9 Q9UKV0 1/20 0.77
HDAC5 Q9UQL6 1/20 0.77
NPC1 O15118 3/20 0.70
RAB9A P51151 3/20 0.70
GAA P10253 1/20 0.59
MAPT P10636 1/20 0.59
NFKB1 P19838 1/20 0.59
NFKB2 Q00653 1/20 0.59
RELA Q04206 1/20 0.59
ALDH1A1 P00352 2/20 0.59
CES2 O00748 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4522324 0.90 HDAC1 (0.69) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL5711050 0.89 HDAC1 (0.68) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL29531380 0.87 NPC1 (0.79) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL2384990 0.87 HDAC1 (1.00) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL30763136 0.87 HDAC3 (0.71) HDAC1HDAC6HDAC3HDAC4HDAC7
Ammonia Solution, Strong SCHEMBL20302203 0.87 MCL1 (0.69) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL30416073 0.87 HDAC1 (1.00) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL5285570 0.87 HDAC3 (0.71) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL12437777 0.87 NPC1 (0.79) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL18906043 0.86 HDAC1 (0.64) HDAC1HDAC6HDAC3HDAC4HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6191146-B1 BACTERICIDES, FUNGICIDES, VIRICIDES SMITHKLINE BEECHAM CORPORATION 2001-02-20 US claimed
US-10910642-B1 Redox flow battery having ligand-metal complex TRIAD NATIONAL SECURITY, LLC (US) 2021-02-02 US disclosed
US-8247399-B2 Photoactive metal nitrosyls for blood pressure regulation and cancer therapy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-08-21 US disclosed
US-20110152230-A1 Photoactive Metal Nitrosyls For Blood Pressure Regulation And Cancer Therapy THE REGENT OF THE UNIVERSITY OF CALIFORNIA 2011-06-23 US disclosed
US-7582623-B2 Ruthenium, manganese and ferric complexes with a polydentate ligand of carboxamide/pyridyl and nitrosyl ; targeted delivery of nitric oxide by applying of low power light; catherization; cysteine protease inhibiters; antitumor/carcinogenic agents; immunotherapy; muscle relaxants; side effect reduction THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-09-01 US disclosed
US-6191146-B1 BACTERICIDES, FUNGICIDES, VIRICIDES SMITHKLINE BEECHAM CORPORATION 2001-02-20 US disclosed
EP-0866700-A4 HEMOREGULATORY COMPOUNDS SMITHKLINE BEECHAM CORP (US) 1999-04-07 EP disclosed
EP-0866700-A1 HEMOREGULATORY COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1998-09-30 EP disclosed
WO-1997017958-A1 HEMOREGULATORY COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1997-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152230-A1 Photoactive Metal Nitrosyls For Blood Pressure Regulation And Cancer Therapy NOS2, NOS3, NOS1 HDAC1 1525/4885HDAC6 2322/4885HDAC3 2435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.